Sreekanth K. Chaguturu - 29 Nov 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Chief Medical Officer
Signature
/s/ Sreekanth K. Chaguturu
Issuer symbol
CVS
Transactions as of
29 Nov 2022
Net transactions value
-$44,589
Form type
4
Filing time
01 Dec 2022, 16:23:20 UTC
Previous filing
02 Sep 2022
Next filing
01 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Tax liability $44,589 -442 -13% $100.88 2,897 29 Nov 2022 Direct F1
holding CVS Common Stock (RSU) 354 29 Nov 2022 Direct F2
holding CVS Common Stock (RSU) 2,154 29 Nov 2022 Direct F3
holding CVS Common Stock (RSU) 1,258 29 Nov 2022 Direct F4
holding CVS Common Stock (RSU) 2,085 29 Nov 2022 Direct F5
holding CVS Common Stock (RSU) 2,776 29 Nov 2022 Direct F6
holding CVS Common Stock (RSU) 6,182 29 Nov 2022 Direct F7
holding CVS Common Stock (RSU) 12,735 29 Nov 2022 Direct F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 4,956 29 Nov 2022 Common Stock 4,956 $75.27 Direct F9
holding CVS Stock Option 9,579 29 Nov 2022 Common Stock 9,579 $58.34 Direct F10
holding CVS Stock Option 9,502 29 Nov 2022 Common Stock 9,502 $74.30 Direct F11
holding CVS Stock Option 12,993 29 Nov 2022 Common Stock 12,993 $101.09 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award.
F2 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse on 2/28/2023.
F3 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F4 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F5 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in two equal installments beginning 2/26/2023.
F6 Consists of RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in three equal installments beginning 4/1/2023.
F7 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments beginning 4/1/2023.
F8 Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
F9 Option became exercisable in four equal annual installments, commencing 11/29/2020.
F10 Option became exercisable in four equal annual installments, commencing 4/1/2021.
F11 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F12 Option becomes exercisable in four equal annual installments, commencing 4/1/2023.